A Response to the Letter to the Editor: Can High-Dose Furmonertinib Effectively Address Unmet Needs in EGFR-Mutated NSCLC With Leptomeningeal Metastases? [0.03%]
对读者来信的回复：高剂量福莫特丁能否有效应对EGFR突变型伴脑膜转移的NSCLC未满足的需求？
Sen Yang,Haiyang Chen,Qiming Wang
Sen Yang
Can a High-Dose of Furmonertinib Effectively Address Unmet Needs in EGFR-Mutated NSCLC with Leptomeningeal Metastases? [0.03%]
高剂量福罗替尼能有效应对EGFR突变型伴脑膜转移的非小细胞肺癌未满足需求吗？
Jiawen Bu,Tong Zhu,Xudong Zhu
Jiawen Bu
Re-Evaluating the Overall Survival Advantage of Segmentectomy: A Missing Perspective on Age [0.03%]
重新评估解剖性段切除术的生存优势：被忽视的年龄因素影响视角
Arif Hakan Önder
Arif Hakan Önder
Reducing Lung Cancer Mortality by Providing Smoking Cessation Support in the Lung Cancer Screening Setting: Missed Opportunities and Lessons Learned on Both Sides of the Atlantic [0.03%]
肺癌筛查中提供戒烟支持以减少肺癌死亡率：大西洋两岸的错失机会和教训
Kathryn L Taylor,Randi M Williams,Rafael Meza et al.
Kathryn L Taylor et al.
National guidelines for the implementation of lung cancer screening (LCS) for high-risk older adults have been issued by several countries, largely in Europe, North America, and Australia. Typically, these guidelines recommend but do not sp...
Lung Cancer in Norway [0.03%]
挪威的肺癌
Odd Terje Brustugun,Bjørn Henning Grønberg,Marianne Aanerud et al.
Odd Terje Brustugun et al.
PD-L1-Overexpressing NSCLC: Overcoming All-Comer Approach and Network Effect to Weather the "Winter" of Cancer Immunotherapy [0.03%]
PD-L1高表达NSCLC：克服“通吃”策略和网络效应的寒冬，让肿瘤免疫治疗进入春天
Fabio Salomone,Antonio Nuccio,Roberto Ferrara
Fabio Salomone
Beyond Programmed Death-Ligand 1: Gut Microbiome Composition as a Biomarker For First-Line Chemoimmunotherapy in Advanced NSCLC [0.03%]
超越程序化细胞死亡配体1：肠道微生物组构成作为晚期非小细胞肺癌一线化疗免疫治疗生物标志物的研究
Prodromos Koutoukoglou,Giannis Mountzios
Prodromos Koutoukoglou
Is Camrelizumab Plus Chemotherapy With or Without Radiotherapy Effective in NSCLC With Brain Metastases? [0.03%]
卡瑞利珠单抗联合化疗和/或放疗治疗伴脑转移的非小细胞肺癌有效吗？
Guntulu Ak,Selma Metintas,Muzaffer Metintas
Guntulu Ak
NSCLC Immunogenomics in People Living With HIV: Details Make the Difference [0.03%]
人类免疫缺陷病毒携带者非小细胞肺癌免疫组学：细节产生差异
Sara Pilotto,Umberto Malapelle
Sara Pilotto
50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow's Guide in the Clinic [0.03%]
非小细胞肺癌的50年进展：临床新指南
Jarushka Naidoo,Abesh Niroula,Dipesh Uprety et al.
Jarushka Naidoo et al.